Single-nucleotide polymorphisms of MMP-2 gene in stroke subtypes

Cerebrovascular Diseases

Volumn 26, Issue 2, 2008, Pages 113-119

  Fatar, Marc ^b   Stroick, Mark ^b   Steffens, Michael ^d   Senn, Eva ^b   Reuter, Bjoern ^b   Bukow, Simone ^b   Griebe, Martin ^b   Alonso, Angelika ^b   Lichtner, Peter ^c   Bugert, Peter ^a   Meitinger, Thomas ^c   Wienker, Thomas F ^d   Hennerici, Michael G ^b  

^a Institute of Transfusion Medicine and Immunology   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

Lacunes; Matrix metalloproteinases; Small vessel disease; Stroke

Indexed keywords

GELATINASE A;

ADULT; AGED; ARTICLE; CAROTID ARTERY OBSTRUCTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DNA DETERMINATION; ECHOGRAPHY; ENZYME BLOOD LEVEL; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEMORRHAGIC STROKE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROANGIOPATHY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STROKE;

EID: 49949084655     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000139657     Document Type: Article

References (51)

1. Fatar M, Stroick M, Griebe M, Hennerici M: Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis 2005;20:141-151.
2. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P: Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann NY Acad Sci 1995;748:501-507.
3. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503.
4. Buja LM and Willerson JT: Role of inflammation in coronary plaque disruption. Circulation 1994;89:503-505.
5. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT: Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation 1994;90:775-778.
6. Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, Welgus HG, Wickline SA, Parks WC: Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 1996;93:9748-9753.
7. Ghilardi G, Biondi ML, DeMonti M, Turri O, Guagnellini E, Scorza R: Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis. Stroke 2002;33:2408-2412.
8. Kuroiwa T, Ting P, Martinez H, Klatzo I: The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. Acta Neuropathol (Berl) 1985;68:122-129.
9. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ: Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999;19:624-633.
10. Kelly MA, Shuaib A, Todd KG: Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp Neurol 2006;200:38-49.
11. Shigemori Y, Katayama Y, Mori T, Maeda T, Kawamata T: Matrix metalloproteinase-9 is associated with blood-brain barrier opening and brain edema formation after cortical contusion in rats. Acta Neurochir Suppl 2006;96:130-133.
12. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J: Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598-603.
13. Fitch MT, Doller C, Combs CK, Landreth GE, Silver J: Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. J Neurosci 1999;19:8182-8198.
14. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC: Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998;29:1020-1030.
15. Galis ZS, Sukhova GK, Libby P: Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995;9:974-980.
16. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR: Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 1997;238:53-56.
17. Rosenberg GA, Sullivan N, Esiri MM: White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke 2001;32:1162-1168.
18. Yamada T, Yoshiyama Y, Sato H, Seiki M, Shinagawa A, Takahashi M: White matter microglia produce membrane-type matrix metalloprotease, an activator of gelatinase A, in human brain tissues. Acta Neuropathol (Berl) 1995;90:421-424.
19. Tost J, Gut IG: Genotyping single nucleotide polymorphisms by MALDI mass spectrometry in clinical applications. Clin Biochem 2005;38:335-350.
20. Sasieni PD: From genotypes to genes: doubling the sample size. Biometrics 1997;53:1253-1261.
21. Rothman KJ: No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-46.
22. Nielsen DM, Ehm MG, Weir BS: Detecting marker-disease association by testing for Hardy-Weinberg disequilibrium at a marker locus. Am J Hum Genet 1998;63:1531-1540.
23. Fisher CM: Lacunes: small, deep cerebral infarcts: 1965. Neurology 1998;50:841.
24. Armstrong CA, Bevan SN, Gormley KT, Markus HS, Koblar SA: Tissue plasminogen activator -7351C/T polymorphism and lacunar stroke. Stroke 2006;37:329.
25. Gormley K, Bevan S, Markus HS: Polymorphisms in genes of the renin-angiotensin system and cerebral small vessel disease. Cerebrovasc Dis 2007;23:148-155.
26. Hassan A, Gormley K, O'Sullivan M, Knight J, Sham P, Vallance P, Bamford J, Markus H: Endothelial nitric oxide gene haplotypes and risk of cerebral small-vessel disease. Stroke 2004;35:654-659.
27. Gormley K, Bevan S, Hassan A, Markus HS: Polymorphisms in genes of the endothelin system and cerebral small-vessel disease. Stroke 2005;36:1656-1660.
28. Markus HS, Barley J, Lunt R, Bland JM, Jeffery S, Carter ND, Brown MM: Angiotensin-converting enzyme gene deletion polymorphism: a new risk factor for lacunar stroke but not carotid atheroma. Stroke 1995;26:1329-1333.
29. Zhang JH, Kohara K, Yamamoto Y, Nakura J, Tabara Y, Fujisawa M, Katagi R, Miki T: Genetic predisposition to neurological symptoms in lacunar infarction. Cerebrovasc Dis 2004;17:273-279.
30. Chamorro A, Revilla M, Obach V, Vargas M, Planas AM: The -174G/C polymorphism of the interleukin 6 gene is a hallmark of lacunar stroke and not other ischemic stroke phenotypes. Cerebrovasc Dis 2005;19:91-95.
31. Revilla M, Obach V, Cervera A, Davalos A, Castillo J, Chamorro A: A -174G/C polymorphism of the interleukin-6 gene in patients with lacunar infarction. Neurosci Lett 2002;324:29-32.
32. Tachikawa H, Tsuda M, Onoe K, Ueno M, Takagi S, Shinohara Y: Alpha-1-antichymotrypsin gene A1252G variant (ACT Isehara-1) is associated with a lacunar type of ischemic cerebrovascular disease. J Hum Genet 2001;46:45-47.
33. Furuta A, Ishii N, Nishihara Y, Horie A: Medullary arteries in aging and dementia. Stroke 1991;22:442-446.
34. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC: Subcortical ischaemic vascular dementia. Lancet Neurol 2002;1:426-436.
35. Mulvany MJ: Small artery remodeling and significance in the development of hypertension. News Physiol Sci 2002;17:105-109.
36. D'Armiento J: Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc Med 2002;12:97-101.
37. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Tinelli C, Cicero AF: Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006;13:227-231.
38. Song W and Ergul A: Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: relation to vessel size. Cardiovasc Diabetol 2006;5:3.
39. Thrailkill KM, Bunn RC, Moreau CS, Cockrell GE, Simpson PM, Coleman HN, Frindik JP, Kemp SF, Fowlkes JL: Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care 2007;30:2321-2326.
40. Derosa G, D'Angelo A, Tinelli C, Devangelio E, Consoli A, Miccoli R, Penno G, Del Prato S, Paniga S, Cicero AF: Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab 2007;33:129-134.
41. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E: Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 1995;201:223-226.
42. Esiri MM, Wilcock GK, Morris JH: Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry 1997;63:749-753.
43. Akiguchi I, Tomimoto H, Suenaga T, Wakita H, Budka H: Alterations in glia and axons in the brains of Binswanger's disease patients. Stroke 1997;28:1423-1429.
44. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH: Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 1997;23:406-415.
45. Ravens JR: Vascular changes in the human senile brain. Adv Neurol 1978;20:487-501.
46. Duvernoy HM, Delon S, Vannson JL: Cortical blood vessels of the human brain. Brain Res Bull 1981;7:519-579.
47. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA: Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007;27:697-709.
48. Vukasovic I, Tesija-Kuna A, Topic E, Supanc V, Demarin V, Petrovcic M: Matrix metalloproteinases and their inhibitors in different acute stroke subtypes. Clin Chem Lab Med 2006;44:428-434.
49. Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S: Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003;34:2165-2170.
50. Chang DI, Hosomi N, Lucero J, Heo JH, Abumiya T, Mazar AP, del Zoppo GJ: Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J Cereb Blood Flow Metab 2003;23:1408-1419.
51. Djonov V, Cresto N, Aebersold DM, Burri PH, Altermatt HJ, Hristic M, Berclaz G, Ziemiecki A, Andres AC: Tumor cell specific expression of MMP-2 correlates with tumor vascularisation in breast cancer. Int J Oncol 2002;21:25-30